SBIO

ALPS Medical Breakthroughs ETF
*Unless otherwise stated, data provided by FactSet.

SBIO Fund Description

SBIO tracks the Poliwogg Medical Breakthroughs Index, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

SBIO Factset Analytics Insight

If you're looking for broad biotech exposure, you won't find it in SBIO; the fund targets biotech companies with drugs in Phase II and Phase III of FDA clinical trials, and limits itself to US-listed firms with market caps between $200M and $5B. SBIO also screens for sustainability—meaning constituent firms have enough cash on hand to last 2 years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. SBIO's Tradability isn't bad for a specialty fund, with decent volume and sizeable spreads, and its underlying liquidity is good. It charges a middling fee for a niche fund, which may give it an edge over its more expensive rival, BBC.

SBIO MSCI ESG Analytics Insight

ALPS Medical Breakthroughs ETF has an MSCI ESG Fund Rating of BB based on a score of 3.27 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ALPS Medical Breakthroughs ETF ranks in the 12nd percentile within its peer group and in the 20th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

SBIO Charts And Performance

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 07/09/20] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
SBIO 0.96% 23.36% 0.25% 17.10% 16.03% 4.78% --
ticker (NAV) 0.88% 23.01% 0.24% 17.18% 16.07% 4.79% --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

SBIO Summary Data

SS&C
ALPS
12/31/14
Open-Ended Fund
0.50%
$195.24M
$1.46M
0.27%

SBIO Portfolio Data

$2.99B
-16.12
5.14
0.04%
12/21/20
92

SBIO Index Data

S-Network Medical Breakthroughs Index
Market Cap
Fundamental
N/A

SBIO Portfolio Management

0.50%
--
--
--

SBIO Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

SBIO Fund Structure

Open-Ended Fund
No
Yes
100% / 0%
N/A
N/A
Low
Daily
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -

SBIO Factset Analytics Block Liquidity

As of 07/10/20
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.

SBIO Tradability

34,969
$1.46M
32,840
$1.41M
0.27%
$0.11
-0.02%
1.18% / -1.14%
None
0.00%
50,000
0.66
--
0.57%
874
$42.39
5

SBIO Sector/Industry Breakdown


SBIO
Segment Benchmark
88.19%
--
11.81%
--

SBIO Top 10 Holdings[View All]

3.94%
3.83%
3.64%
3.57%
3.50%
3.25%
3.07%
3.00%
2.99%
2.64%
33.43%

SBIO Countries


SBIO
Segment Benchmark
96.25%
--
3.75%
--

SBIO Regions


SBIO
Segment Benchmark
96.25%
--
3.75%
--

SBIO Economic Development


SBIO
Segment Benchmark
100.00%
--

SBIO Performance Statistics

--
--
--
--
0.00%
N/A

SBIO MSCI ESG Ratings

3.27 / 10
20.15
11.53
--
7.25%
26.88

SBIO Benchmark Comparison Holdings

92
--
--
0.00%

SBIO Benchmark Comparison Summary


SBIO
Segment Benchmark
92
--
$2.99B
--
-16.12
--
5.14
--
0.00%
--
Medium
High

SBIO Benchmark Comparison Market Cap Size


SBIO
Segment Benchmark
0.00%
--
49.51%
--
44.07%
--
6.42%
--